XML 37 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1

Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($) $ in Millions		3 Months Ended			12 Months Ended
	Jul. 30, 2013	Mar. 31, 2017	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2015
U.S./RoW [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected upfront, non-contingent and time-based payments	$ 374.0
Development and regulatory approval milestones	550.0
Commercial sales milestone	325.0
Shared development costs				$ 233.0
Additional consideration based on net sales description		Low 20% range
U.S./RoW [Member] | FibroGen, Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Shared development costs				$ 116.5
U.S./RoW [Member] | Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receipt of development milestone payment					$ 15.0
China [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and regulatory approval milestones	161.0
Commercial sales milestone	167.5
Proceeds from upfront payments	28.2
Contingent payment	$ 20.0
Estimated joint development service period			2018
Estimated joint development extended service period			2020

X

- Definition

The amount of additional consideration based on net sales of product as defined under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of milestone payments related to commercial sales under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_CommercialSalesMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the amount of contingent payments provided for under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	fgen_ContingentPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_DevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Development milestone payment received.

+ References

No definition available.

+ Details

Name:	fgen_DevelopmentMilestonePaymentReceived
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Estimated joint development extended service period.

+ References

No definition available.

+ Details

Name:	fgen_EstimatedJointDevelopmentExtendedServicePeriod
Namespace Prefix:	fgen_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Estimated joint development service period.

+ References

No definition available.

+ Details

Name:	fgen_EstimatedJointDevelopmentServicePeriod
Namespace Prefix:	fgen_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the total amount of expected non-contingent upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ExpectedProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the total amount of development costs that will be shared under collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_SharedDevelopmentCosts
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=fgen_FibroGenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: